home / stock / pgnx / pgnx news

PGNX News and Press, Progenics Pharmaceuticals Inc. From 07/08/19

Stock Information
Company Name: Progenics Pharmaceuticals Inc.
Stock Symbol: PGNX
Market: NASDAQ
Website: progenics.com
Menu
PGNX PGNX Quote PGNX Short PGNX News PGNX Articles PGNX Message Board
Get PGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
PGNX - Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

ALPHARETTA, Ga. , July 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialty...
PGNX - Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced the appointment of Huw Jones to the newly created role of Vic...

PGNX - Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

ALPHARETTA, Ga. , July 1, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialt...

PGNX - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote "FOR" ALL of Progenics' Director Nominees

Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance  Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would Grant Velan Direct Board Representation Twice the Size of its Economic Interest...
PGNX - ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

ALPHARETTA, Ga. , June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful sp...

PGNX - Progenics Reiterates Targeted Directors' Indispensable Experience and Leadership Critical to the Company's Long-Term Success

Comments on ISS Report Urges Shareholders to Vote “FOR” All of the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 28, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company&...

PGNX - Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors

ALPHARETTA, Ga. , June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialt...
PGNX - Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital

Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in 2020 Despite Progenics’ Repeated Settlement Concessions, Velan Insists on Terms to Position it for Contr...

PGNX - Progenics up 6% on PyL data in prostate cancer

Progenics Pharmaceuticals ( PGNX +5.9% ) is up on below-average volume on the heels of results from a Phase 2/3 clinical trial, OSPREY , evaluating PSMA-targeted PET imaging agent PyL in men with high-risk metastatic prostate cancer and an investigator-sponsored study assessing PyL in men...

PGNX - Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics' PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted imag...
Previous 10 Next 10